Attending the HIT IT Summit? Don’t miss our presentation on case studies showing how we're leveraging our capabilities and expertise in targeting the chromatin regulatory system and going after targets that were previously considered undruggable: hit-id-summit.com

Our leadership team is looking forward to participating in upcoming investor conferences. Learn more about our fireside chats and catch us at the Jefferies London Healthcare, 7th Annual Evercore ISI CONx, and Citi Global Healthcare conferences: bit.ly/4fEXXM0 $FHTX

Our team is dedicated to making a difference in patients’ lives. Last month, we had the honor of visiting the American Cancer Society’s Hope Lodge Center, where we prepared and served dinner to individuals fighting #cancer and their caregivers.

Our CEO, @AdrianGottschalk, shared insights into Foghorn’s work in the chromatin regulatory system and his perspective on the biotech industry in the latest interview with Onyx. Read it here: bit.ly/4980BaW

Today, we’re especially grateful for our Foghorn team who are dedicated to our mission to transform the lives of people across a wide spectrum of diseases. Happy Thanksgiving, everyone!

Join us at @cellsymposia’s Chemical Biology in Drugging the Undrugged to hear Danette Daniels give an oral presentation about our pioneering work to create medicines that are designed to modulate the chromatin regulatory system. See the agenda: bit.ly/3B93POU

Our Foghorn team had a blast celebrating the season with some fun surprises at our annual Yankee Swap! Wishing everyone a joyful and healthy holiday season from all of us at Foghorn.

We’re kicking off 2025 by sharing our strategic objectives and key progress across programs. With a strong balance sheet and advancing pipeline, we’re poised for an impactful year. Learn more about our plans and progress: bit.ly/407ShEa $FHTX

Did you catch Foghorn CEO Adrian Gottschalk's interview at the Flagship Pioneering studio during #JPM25? Adrian shares insights into our pioneering work with the chromatin regulatory system, pipeline progress, and what’s ahead in 2025: bit.ly/4jJnp67 #FlagshipFounded

We're looking forward to participating in two upcoming investor conferences to participate in a panel on synthetic lethality and give an update on our pioneering work to modulate the chromatin regulatory system. Learn more: bit.ly/41hGCTE $FHTX

Today, we provided a financial update for 2024 and corporate outlook for 2025. Read the announcement to see recent highlights and upcoming catalysts for the company: bit.ly/41s87Ks $FHTX

We’re looking forward to presenting at the 2025 AACR annual meeting! We’ll share new preclinical data on our selective SMARCA2 inhibitor, FHD-909, as well as our Selective CBP and EP300 degrader programs. Learn more: bit.ly/4c1tLtP #AACR25

Join us for our virtual investor event to hear new preclinical data for FHD-909 and our selective degrader programs from AACR, as well as an overview of our Selective ARID1B degrader program: bit.ly/42suDU0 $FHTX

In an interview with BiotechTV, $FHTX CEO Adrian Gottschalk highlighted platform progress, new preclinical data at #AACR25, and how we’re unlocking chromatin biology to advance potential first-in-class medicines.

Exciting progress from Foghorn at #AACR25: New preclinical data on FHD-909 and our selective degrader programs. Plus, be sure to catch the pipeline update during tomorrow’s investor event. Learn more: bit.ly/4d2fr52 $FHTX

A big welcome to Neil Gallagher, M.D., Ph.D., and Stuart Duty as they join $FHTX's BOD. Their leadership and deep industry expertise will be critical as we advance potentially first-in-class therapies across our pipeline. Read more: bit.ly/3GygE7M

We’re heading to the Citizens Life Sciences Conference. CEO Adrian Gottschalk will join a fireside chat on May 7 at 9:30am ET to share insights on our Gene Traffic Control® platform & pipeline, including data presented at #AACR25. More at bit.ly/4d4hupc $FHTX

Foghorn’s Vice President, Protein Degrader Platform, Danette Daniels, recently joined drug hunter to share insights on our selective degrader programs. Watch now: bit.ly/4mumVSL

We continue to advance a robust pipeline of precision medicines targeting the chromatin regulatory system. In our Q1 2025 update today, we shared details on our pipeline progress, including new preclinical data at this year’s AACR annual meeting: bit.ly/3Zff3u6 $FHTX

We're looking forward to several upcoming healthcare conferences over the next few weeks where $FHTX CEO Adrian Gottschalk will highlight our progress and updates across our pipeline. Learn more: bit.ly/3H4F1ua